Target Information
| Target General Infomation | Top | ||||
|---|---|---|---|---|---|
| Target ID |
T88015
|
||||
| Target Name |
COVID-19 3C-like protease (3CLpro)
|
||||
| Synonyms |
COVID-19 3CL-PRO; COVID-19 3CLp; COVID-19 nsp5
|
||||
| Gene Name |
COVID-19 rep
|
||||
| Target Status |
Target in Phase 3 Trial
|
[1] | |||
| Disease | [+] 1 Target-related Diseases | + | |||
| 1 | COVID-19 [ICD-11: 1D6Y] | ||||
| Function |
Cleaves the C-terminus of replicase polyprotein at 11 sites. Recognizes substrates containing the core sequence [ILMVF]-Q-|-[SGACN]. Also able to bind an ADP-ribose-1''-phosphate (ADRP).
|
||||
| BioChemical Class |
Coronaviruses polyprotein 1ab family
|
||||
| UniProt ID | |||||
| EC Number |
EC 3.4.22.69
|
||||
| Sequence |
SGFRKMAFPSGKVEGCMVQVTCGTTTLNGLWLDDVVYCPRHVICTSEDMLNPNYEDLLIR
KSNHNFLVQAGNVQLRVIGHSMQNCVLKLKVDTANPKTPKYKFVRIQPGQTFSVLACYNG SPSGVYQCAMRPNFTIKGSFLNGSCGSVGFNIDYDCVSFCYMHHMELPTGVHAGTDLEGN FYGPFVDRQTAQAAGTDTTITVNVLAWLYAAVINGDRWFLNRFTTTLNDFNLVAMKYNYE PLTQDHVDILGPLSAQTGIAVLDMCASLKELLQNGMNGRTILGSALLEDEFTPFDVVRQC SGVTFQ |
||||
| Drugs and Modes of Action | Top | ||||
|---|---|---|---|---|---|
| Drugs in Phase 3 Trial | [+] 5 Drugs in Phase 3 Trial | + | |||
| 1 | Lopinavir + ritonavir | Drug Info | Phase 3 Trial | COVID-19 | [2] |
| 2 | ASC09 + ritonavir + oseltamivir | Drug Info | Phase 3 Trial | COVID-19 | [3] |
| 3 | Lopinavir + ritonavir + favipiravir | Drug Info | Phase 3 Trial | COVID-19 | [4] |
| 4 | Darunavir + cobicistat | Drug Info | Phase 3 Trial | COVID-19 | [5] |
| 5 | Lopinavir + ritonavir + oseltamivir | Drug Info | Phase 3 Trial | COVID-19 | [4] |
| Drugs in Phase 2 Trial | [+] 1 Drugs in Phase 2 Trial | + | |||
| 1 | Lopinavir + ritonavir + ribavirin + interferon beta-1b | Drug Info | Phase 2 Trial | COVID-19 | [6] |
| Drugs in Phase 1 Trial | [+] 2 Drugs in Phase 1 Trial | + | |||
| 1 | Lopinavir + ritonavir + interferon apha + traditional chinese medicines granules | Drug Info | Phase 1 Trial | COVID-19 | [7] |
| 2 | ASC09 + ritonavir | Drug Info | Phase 1 Trial | COVID-19 | [8] |
| Preclinical Drugs | [+] 1 Preclinical Drugs | + | |||
| 1 | Lopinavir + ritonavir + interferon alpha | Drug Info | Preclinical | COVID-19 | [9] |
| Investigative agents | [+] 2 Investigative agents | + | |||
| 1 | GC376 | Drug Info | Investigative | COVID-19 | [10] |
| 2 | Boceprevir | Drug Info | Investigative | COVID-19 | [10] |
| Mode of Action | [+] 1 Modes of Action | + | |||
| Inhibitor | [+] 11 Inhibitor drugs | + | |||
| 1 | ASC09 + ritonavir | Drug Info | [1] | ||
| 2 | ASC09 + ritonavir + oseltamivir | Drug Info | [1] | ||
| 3 | Darunavir + cobicistat | Drug Info | [1] | ||
| 4 | Lopinavir + ritonavir | Drug Info | [1] | ||
| 5 | Lopinavir + ritonavir + favipiravir | Drug Info | [1] | ||
| 6 | Lopinavir + ritonavir + oseltamivir | Drug Info | [1] | ||
| 7 | Lopinavir + ritonavir + ribavirin + interferon beta-1b | Drug Info | [1] | ||
| 8 | Lopinavir + ritonavir + interferon apha + traditional chinese medicines granules | Drug Info | [1] | ||
| 9 | GC376 | Drug Info | [10] | ||
| 10 | Lopinavir + ritonavir + interferon alpha | Drug Info | [1] | ||
| 11 | Boceprevir | Drug Info | [10] | ||
| References | Top | ||||
|---|---|---|---|---|---|
| 1 | Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381. | ||||
| 2 | ClinicalTrials.gov (NCT04315948) Trial of Treatments for COVID-19 in Hospitalized Adults | ||||
| 3 | ClinicalTrials.gov (NCT04261270) A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia | ||||
| 4 | ClinicalTrials.gov (NCT04303299) Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID-19 : A Randomized Control Trial | ||||
| 5 | ClinicalTrials.gov (NCT04252274) Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19 | ||||
| 6 | ClinicalTrials.gov (NCT04276688) Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment | ||||
| 7 | ClinicalTrials.gov (NCT04251871) Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection | ||||
| 8 | ClinicalTrials.gov (NCT04261907) Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection | ||||
| 9 | ClinicalTrials.gov (NCT04275388) Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia | ||||
| 10 | Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. 2020. April 20. doi: https://doi.org/10.1101/2020.04.20.051581 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.